Abstract
10x Genomics, Inc. will report its quarterly results on November 05, 2026 Post-Mkt; consensus currently points to modest year-over-year revenue growth with a narrower adjusted loss, while investors will focus on revenue mix, margin resilience, and spending discipline.Market Forecast
Market expectations for the upcoming quarter indicate revenue of 147.86 million US dollars, up 3.77% year over year; adjusted EPS is projected at -0.26, reflecting a 9.02% year-over-year improvement, while EBIT is estimated at -36.70 million US dollars, a year-over-year decline of 38.12%. Forecasts for gross profit margin and net margin are not formally provided in the current consensus and are therefore omitted. Core consumables remain the primary revenue driver and are expected to underpin stability in the quarter, with instruments constrained by cautious customer capital budgets and services providing incremental growth. The most promising revenue stream continues to be products and services, which delivered 149.90 million US dollars in the first quarter of 2026, up 9% year over year, and is expected to support this quarter’s top line through higher assay utilization.Last Quarter Review
In the previous quarter, 10x Genomics, Inc. reported revenue of 151.04 million US dollars (down 12.65% year over year), a gross profit margin of 74.48%, a GAAP net loss attributable to the parent of 17.93 million US dollars with a net margin of -11.87%, and adjusted EPS of -0.14 (year-over-year change of -150%). A notable highlight was that revenue exceeded the pre-report estimate by 4.25 million US dollars and adjusted EPS also beat the estimate by 0.10, reflecting better-than-modeled execution on both cost control and top-line delivery. By business line, consumables contributed 130.75 million US dollars, services 10.68 million US dollars, instruments 7.66 million US dollars, and licenses and royalties 1.94 million US dollars; at the company level revenue declined 12.65% year over year in the quarter, while earlier in 2026 the license-and-royalty line showed pronounced year-over-year pressure, underscoring a mix skewed toward recurring products and services.Current Quarter Outlook
Main business outlook
The core of the quarter’s narrative is the consumables franchise, which anchors most of the company’s revenue and continues to benefit from rising utilization across the installed base. The recent mix of assay adoption suggests depth in recurring revenue, with flexible formats and next-generation chemistries designed to encourage higher reaction volumes per project. Against this supportive utilization backdrop, instruments remain a more variable line given customer capital-spending cycles; consequently, the company’s cost control and gross-margin leverage depend on maintaining a consumables-heavy revenue mix. Margin watchers will benchmark the quarter against last quarter’s 74.48% gross margin, recognizing that mix, pricing discipline, and manufacturing scale efficiencies drive reported results. On operating expenses, prior-quarter discipline contributed to the adjusted EPS outperformance; any sustained moderation in spend should help offset headwinds from instruments and support the projected year-over-year improvement in adjusted EPS to -0.26.Management’s prior communications and recent momentum in recurring assays imply a continued emphasis on throughput and workflow productivity, which can help stabilize revenue even in a cautious funding environment. Operationally, shipment timing and end-of-quarter order fulfillment can affect intra-quarter volatility, but the consensus track for 147.86 million US dollars suggests a manageable revenue cadence. The company’s own track record of delivering above model last quarter gives investors a clear benchmark for execution this quarter, with attention on whether recurring revenue can offset any pockets of instrument softness.
Most promising business
The most promising growth engine remains products and services, which reached 149.90 million US dollars in the first quarter of 2026, up 9% year over year, demonstrating evidence of sustained adoption and recurring utilization. Within this revenue stream, newer chemistries and spatial workflows are designed to increase sample throughput and deepen per-project consumables intensity, thereby strengthening the revenue base tied to recurring purchases rather than one-off capital equipment. In the near term, commercialization of recently introduced platforms is expected to feed demand for complementary consumables, adding breadth to the consumables mix and creating practical opportunities for cross-sell within the company’s portfolio. The path to this quarter’s forecast implies that products-and-services momentum should remain pivotal to meeting or exceeding the 147.86 million US dollars revenue target, particularly if instrumentation continues to reflect disciplined customer budgeting. The combination of high-margin recurring revenue and an expanding library of assays and kits provides a framework for incremental margin resilience, even as the company manages the operating expense envelope to support earnings trajectory.Beyond near-term revenue contribution, early commercialization steps for new platforms are expected to expand the addressable workload on existing systems, improving consumables pull-through per instrument. This dynamic supports the thesis that incremental platform introductions can catalyze recurring revenue without requiring a commensurate rise in capital placements. For this quarter, the measurable impact will be judged by recurring revenue growth, attach rates, and any disclosure on utilization metrics, with the improvement in adjusted EPS serving as an output measure of both top-line mix and spending discipline.
What will most impact the stock this quarter
The single most influential factor for the stock is whether revenue and adjusted EPS align with or exceed consensus, specifically the 147.86 million US dollars revenue and -0.26 adjusted EPS markers. Investors will scrutinize the revenue mix for confirmation that recurring consumables and services are absorbing volatility in instruments; a favorable mix would also support gross margin performance relative to last quarter’s 74.48%. On profitability, the consensus-implied improvement in adjusted EPS hinges on a balance between operating efficiency and steady consumables demand; any unexpected rise in operating expenses or adverse mix shifts could widen the gap to the -0.26 expectation.Another focal point is the pattern of order intake and shipment timing for new and existing platforms, including any commentary on backlog conversion or lead times that might influence the near-term revenue cadence. Incremental updates on platform rollouts and early customer adoption trends will be closely watched for signals about potential acceleration in recurring revenue in subsequent quarters. Lastly, one-time items remain a background consideration; while not central to the consensus, they can affect reported GAAP results and should be monitored for impact on net loss and margin comparability. Ultimately, the market’s reaction will likely be governed by how well recurring revenue dynamics and operating discipline translate into meeting or modestly beating the forecast profile already embedded in expectations.
Analyst Opinions
Bullish views currently hold the majority over bearish opinions in observable coverage within the January 01, 2026 to October 29, 2026 window, with at least two well-known institutions articulating positive stances and no explicit bearish calls identified in the same period. Barclays, via analyst Luke Sergott, maintained a Buy rating and cited a 110.00 US dollars price target, signaling confidence that execution on the product roadmap and recurring-revenue mix can support valuation upside relative to current expectations. Argus Research initiated with a Buy and a 110.00 US dollars price target, emphasizing the potential of newer platforms to augment recurring revenue and create a favorable mix profile that could underpin both revenue stability and margin durability.Supportive, though not necessarily outright bullish, signals came from other institutions adjusting targets upwards, which provides additional context for the bullish skew. Bank of America raised its price target to 80.00 US dollars, reflecting greater confidence in near-term execution and revenue durability despite a still-challenging capital environment for customers. The cluster of neutral stances, including sector-perform and equal-weight ratings with targets in the mid-to-high double digits, rounds out a spectrum of views that, while cautious, do not contradict the bullish case centered on recurring revenue strength and the emerging contribution from recently commercialized platforms.
The bullish majority’s thesis hinges on three practical pillars for the upcoming print. First, recurring consumables and services provide a foundation for stable quarter-to-quarter revenue and higher gross margin compared with capital equipment sales; this is consistent with last quarter’s gross margin of 74.48% and the consensus expectation for a modest year-over-year revenue increase of 3.77% this quarter. Second, new platform commercialization steps—particularly those announced in recent months—are seen as catalysts to pull through additional consumables, improving per-instrument revenue productivity and helping to narrow adjusted losses; this aligns with the forecasted 9.02% year-over-year improvement in adjusted EPS to -0.26. Third, the company’s ongoing expense discipline is expected to remain a visible driver of earnings quality; last quarter’s performance exceeded pre-report estimates on both revenue and EPS, and bullish analysts anticipate a repeatable operating rhythm that keeps EBIT and EPS within or better than guided ranges even if instruments remain variable.
In synthesizing these views, the bullish camp anticipates that the company’s revenue mix should provide adequate cushion for the projected 147.86 million US dollars top line and -36.70 million US dollars EBIT, with potential upside if recurring revenue trends outperform internal assumptions. The lens on success for this print is less about wholesale acceleration and more about consistency: demonstrating that consumables utilization, services activity, and controlled operating expenses can collectively deliver the incremental improvements already embedded in consensus. Analysts leaning bullish argue that meeting these benchmarks could support constructive revisions to forward estimates, particularly if management provides incremental clarity on the ramp of newly commercialized platforms and the sustainability of gross margin in the mid-70s.
To conclude the prevailing view, bullish opinions outweigh bearish ones in the current observation window, led by Buy ratings from Barclays and Argus and corroborated by upward price-target revisions elsewhere. Their central argument is that the company’s revenue mix, margin profile, and expense control provide a credible basis for achieving the quarter’s modest growth and improved adjusted EPS trajectory, while early commercialization signals offer optionality for medium-term acceleration. The upcoming report on November 05, 2026 Post-Mkt is therefore framed by these expectations: steady recurring revenue, disciplined spending, and clear commentary on the path for new platforms to deepen recurring revenue in subsequent quarters.
Comments